Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
José Angel García Hinojosa, vice president sales and marketing of the Grupo Loeffler Russek, discusses the history of the company since its establishment until its most recent accomplishments. Always with…
Landsteiner is betting on biotech and genomics. The head of new developments and the head of genomic research share their views on the future of the company as well as…
The president and founder of Knobloch Information Group, the leading supplier of market data to the pharmaceutical industry in Mexico, provides an in-depth overlook about the most important changes that…
Innovation is a product’s added value, ensuring that the patient is ready to buy. The former director of R&D and today CEO of Carnot explains how the company is undergoing…
Pablo Escandón shares his experience as CEO of Nadro and how retail changes have transformed the Mexican market, his perspectives on the accessibility of medicine for Mexicans and the challenges…
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Philips aims at becoming the leading provider of solutions across the full ‘continuum of care’. The general manager of the healthcare division in Mexico explains how the company has made…
seca is turning ten years old in Mexico in 2015. The general director of the Mexico affiliate discusses how the company foresaw the growing demand for medical measuring systems and…
‘Poverty is fought with health, education and, above all, employment and more employment’. This is the vision Carlos Slim has for Mexico. The CEO of the Carlos Slim Foundation discusses…
The general manager for Mexico, Central America and Caribbean shares his point of view about the announced healthcare reform, the opportunities and challenges it presents and how BD is adapting…
Worldwide, Bayer is experiencing a strong business momentum thanks to an avalanche of innovation. The general manager of Bayer HealthCare Pharmaceuticals in Mexico shares his perspectives about the recent developments…
After Brazil, Torrent is looking to strengthen its foothold in the Mexican market. The general manager of the local affiliate explains the opportunities Latin America offers to Indian companies, how…
See our Cookie Privacy Policy Here
